Veldoreotide
Also known as: CAM2029-veldoreotide, CHZ840, ZR-0080
Source Veldoreotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Veldoreotide (formerly CHZ840/ZR-0080) is a next-generation, pan-somatostatin receptor analogue developed by Camurus/Novartis. It has a unique receptor binding profile covering SSTR2, SSTR4, and SSTR5, differentiating it from first-generation analogues like octreotide (SSTR2/5-selective). It is being investigated for acromegaly and neuroendocrine tumors, with a subcutaneous depot formulation using FluidCrystal technology intended to provide sustained release with less frequent dosing.
Mechanism of Action
Binds to somatostatin receptors (SSTR2, SSTR4, and SSTR5) with high affinity, inhibiting growth hormone secretion, IGF-1 production, and potentially exerting anti-proliferative effects on neuroendocrine tumor cells.
Routes of Administration
Goals & Uses
- Neuroendocrine tumor (NET) managementOncologyLow
- GH suppressionEndocrinologyModerate
- Symptom relief in carcinoid syndromeGastroenterology/OncologyLow
- IGF-1 normalizationBiomarker / Surrogate EndpointModerate
- Acromegaly controlEndocrinologyModerate
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Hypersensitivity to veldoreotide or somatostatin analoguesAllergyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- Hyperglycemia or hypoglycemiaMetabolic/EndocrineUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Cholelithiasis (gallstone formation)HepatobiliaryUncommon
- Gastrointestinal disturbances (nausea, diarrhea, abdominal discomfort)GastrointestinalCommon
- BradycardiaCardiovascularUncommon
Drug Interactions
- QT-prolonging drugsModerate
- CyclosporineModerate
- Bromocriptine / dopamine agonistsLow
- Insulin / Oral antidiabetic agentsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Patients with hepatic impairmentOrgan FunctionRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Diabetic PatientsMetabolicRelative
Regulatory Status
- European UnionInvestigationalClinical trials conducted in EU. No EMA marketing authorization granted.
- United StatesInvestigationalInvestigated under IND for acromegaly and NETs. No FDA approval as of knowledge cutoff.
- United KingdomInvestigationalNo MHRA approval; investigational status only.
Not approved in any jurisdiction as of the knowledge cutoff. Phase 2 clinical trials conducted. Investigated under IND/clinical trial frameworks in the US and EU.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Veldoreotide?
Veldoreotide (formerly CHZ840/ZR-0080) is a next-generation, pan-somatostatin receptor analogue developed by Camurus/Novartis. It has a unique receptor binding profile covering SSTR2, SSTR4, and SSTR5, differentiating it from first-generation analogues like octreotide (SSTR2/5-selective). It is being investigated for acromegaly and neuroendocrine tumors, with a subcutaneous depot formulation using FluidCrystal technology intended to provide sustained release with less frequent dosing.
What is Veldoreotide used for?
Veldoreotide is educationally associated with: Neuroendocrine tumor (NET) management, GH suppression, Symptom relief in carcinoid syndrome, IGF-1 normalization, Acromegaly control. Educational only — not medical advice.
How is Veldoreotide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Veldoreotide?
Reported adverse effects include: Hyperglycemia or hypoglycemia, Injection site reactions, Headache, Cholelithiasis (gallstone formation), Gastrointestinal disturbances (nausea, diarrhea, abdominal discomfort), Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Veldoreotide?
Recorded contraindications: Severe hepatic impairment, Hypersensitivity to veldoreotide or somatostatin analogues, Pregnancy. Consult a qualified clinician before use.